Literature DB >> 15760726

Stability of different formulations and ion pairs of hypericin.

Ann Huygens1, Appolinary R Kamuhabwa, Peter A M de Witte.   

Abstract

Hypericin, solubilized in an instillation fluid consisting of an aqueous buffer supplemented with 1% plasma proteins, is currently used as a clinical diagnostic tool for the detection of superficial TCC (transitional cell carcinoma) tumors. However, the development of a sterile and stable hypericin stock formulation, excluding the presence of plasma constituents, would be an important factor in a more general clinical application of the method. Therefore, we investigated the stability of several heat sterilized hypericin formulations and ion pairs. Besides sodium hypericinate (in distilled water, in phosphate buffer, in polyethyleneglycol (PEG) 400), several other hypericinate salts (potassium, lysine, TRIS or hexylamine) were investigated. As to that, the physical appearance of different hypericin concentrates stored at 4 and 37 degrees C was investigated. Besides, after dilution into cell culture medium, the ability of hypericin remaining to accumulate in tumor cells and demonstrating photocytotoxic effects upon light irradiation was assessed. These findings suggest that PEG 400 is an excellent hypericin formulation, since it maintained the stability of the compound for at least 120 d when stored at either 4 or 37 degrees C. PEG 400 therefore is a suitable vehicle for the storage of hypericin prior to preparation of the bladder instillation solution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15760726     DOI: 10.1016/j.ejpb.2004.09.014

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  1 in total

1.  Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.

Authors:  Marlein Miranda Cona; Yeranddy Aguiar Alpizar; Junjie Li; Matthias Bauwens; Yuanbo Feng; Ziping Sun; Jian Zhang; Feng Chen; Karel Talavera; Peter de Witte; Alfons Verbruggen; Raymond Oyen; Yicheng Ni
Journal:  Pharm Res       Date:  2013-08-09       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.